We aimed to explore the prognostic value of patient-reported health-related quality of life (HRQoL) data for the achievement of early molecular response (EMR) at 3 months in patients with chronic phase chronic myeloid leukemia (CP-CML). We analyzed HRQoL baseline data of 436 newly diagnosed patients with CML patients enrolled in the GIMEMA Sustrenim trial. HRQoL was assessed by the EORTC QLQ-30 and the QLQ-CML24 questionnaires. In the multivariate analysis, the following factors were found to be independently associated with achievement of EMR: Sokal risk (low vs intermediate risk p=0.046 and low vs high risk p<0.001), nilotinib treatment (p<0.001) and higher patient-reported role functioning (EORTC QLQ-C30) (p<0.001). Current findings suggest the importance of assessing HRQoL at diagnostic workup of patients with CML as it may provide valuable prognostic information.
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial / Efficace, F., Cannella, L., Capodanno, I., Sancetta, R., Porcu, V., Lunghi, M., Biagi, A., Castagnetti, F., Caocci, G., Baldi, T., Marasca, R., Bonifacio, M., Gozzini, A., Martino, B., Sora, F., Westerweel, P.E., Fazi, P., Vignetti, M., Pane, F., Breccia, M.. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 15:(2025), pp. 01-06. [10.3389/fonc.2025.1645217]
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial
Marasca R.;
2025
Abstract
We aimed to explore the prognostic value of patient-reported health-related quality of life (HRQoL) data for the achievement of early molecular response (EMR) at 3 months in patients with chronic phase chronic myeloid leukemia (CP-CML). We analyzed HRQoL baseline data of 436 newly diagnosed patients with CML patients enrolled in the GIMEMA Sustrenim trial. HRQoL was assessed by the EORTC QLQ-30 and the QLQ-CML24 questionnaires. In the multivariate analysis, the following factors were found to be independently associated with achievement of EMR: Sokal risk (low vs intermediate risk p=0.046 and low vs high risk p<0.001), nilotinib treatment (p<0.001) and higher patient-reported role functioning (EORTC QLQ-C30) (p<0.001). Current findings suggest the importance of assessing HRQoL at diagnostic workup of patients with CML as it may provide valuable prognostic information.
| File | Dimensione | Formato | |
|---|---|---|---|
|
fonc-15-1645217.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Licenza:
[IR] creative-commons
Dimensione
387.79 kB
Formato
Adobe PDF
|
387.79 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
